Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220194
Status:
COMPLETED
Last Update Posted:
2016-10-14
First Post:
2005-09-17
Brief Title:
A Six-Month Open-Label Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 225 Mg And Eligard 225 Mg Or Zoladex 108 Mg And Eligard 225 Mg In Patients With Advanced Prostate Cancer
Sponsor:
San Bernardino Urological Associates Medical Group Inc
Organization:
San Bernardino Urological Associates Medical Group Inc
Study Overview
Official Title:
A Six-Month Open-Label Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 225 Mg And Eligard 225 Mg Or Zoladex 108 Mg And Eligard 225 Mg In Patients With Advanced Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparing the effect of switching from Lupron and Zoladex to Eligard PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Sanofi Aventis | None | None | None |